Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

inhibit growth of multiple cancer cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FGFR (1) Akt (3) Apoptosis (6) Aryl Hydrocarbon Receptor (1) Autophagy (3) Bcl-2 Family (1) Checkpoint Kinase (Chk) (1) DNA/RNA Synthesis (1) Endogenous Metabolite (1) Epigenetic Reader Domain (1) GLUT (1) Influenza Virus (3) Interleukin Related (1) Lactate Dehydrogenase (1) Lipoxygenase (1) Microtubule/Tubulin (3) Opioid Receptor (1) Oxidative Phosphorylation (1) PI3K (3) PROTACs (1) Proteasome (1) TNF Receptor (2) α-synuclein (1)
By Research Areas:	Cancer (16) Infection (4) Inflammation/Immunology (5) Neurological Disease (1)

By Targets:

FGFR (1)

Akt (3)

Apoptosis (6)

Aryl Hydrocarbon Receptor (1)

Autophagy (3)

Bcl-2 Family (1)

Checkpoint Kinase (Chk) (1)

DNA/RNA Synthesis (1)

Endogenous Metabolite (1)

Epigenetic Reader Domain (1)

GLUT (1)

Influenza Virus (3)

Interleukin Related (1)

Lactate Dehydrogenase (1)

Lipoxygenase (1)

Microtubule/Tubulin (3)

Opioid Receptor (1)

Oxidative Phosphorylation (1)

PI3K (3)

PROTACs (1)

Proteasome (1)

TNF Receptor (2)

α-synuclein (1)

By Research Areas:

Cancer (16)

Infection (4)

Inflammation/Immunology (5)

Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) BCRP FGFR GHR VEGFR TGF-beta/Smad PDGFR TGF-β Receptor GHSR EGFR IGF-1R Nuclear Hormone Receptor 4A/NR4A

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-141877B

MS4322 (isomer) YS43-22 (isomer)	PROTACs	Cancer
MS4322 (YS43-22) isomer is an isomer of MS4322. MS4322 is a potent and selective PRMT5 (protein arginine methyltransferase 5) degrader, and inhibits growth of multiple cancer cell lines .

HY-136121

Tubulin inhibitor 6	Microtubule/Tubulin	Cancer
Tubulin inhibitor 6 (Compound 14b) is a tubulin inhibitor and a potent inhibitor of multiple cancer cell lines. Tubulin inhibitor 6 inhibits tubulin polymerization with an IC₅₀ of 0.87 μM. Tubulin inhibitor 6 inhibits K562 cell growth with an IC₅₀ of 840 nM .

HY-117102

ANI-7	Aryl Hydrocarbon Receptor Checkpoint Kinase (Chk)	Cancer
ANI-7 is an activator of aryl hydrocarbon receptor (AhR) pathway. ANI-7 inhibits the growth of multiple cancer cells, and potently and selectively inhibits the growth of MCF-7 breast cancer cells with a GI₅₀ of 0.56 μM. ANI-7 induces CYP1-metabolizing mono-oxygenases by activating AhR pathway, and also induces DNA damage, checkpoint Kinase 2 (Chk2) activation, S-phase cell cycle arrest, and cell death in sensitive breast cancer cell lines .

HY-149672

ABBV-467	Bcl-2 Family Apoptosis	Cancer
ABBV-467 is a selective MCL-1 inhibitor (K_i: <0.01 nM). ABBV-467 induces apoptosis. ABBV-467 induces cancer cell death and inhibits tumor growth in models of hematological malignancies, such as multiple myeloma .

HY-115537

NAE-IN-M22	Apoptosis	Cancer
NAE-IN-M22 is a potent, selective and reversible inhibitor of NEDD8 activating enzyme (NAE), with potency in micromolar range. NAE-IN-M22 inhibits multiple cancer cell lines and induces apoptosis in A549 cells. NAE-IN-M22 also can inhibit tumor growth in vivo .

HY-N0103

Sophocarpine 5 Publications Verification	Autophagy Apoptosis PI3K Akt Influenza Virus	Infection Inflammation/Immunology Cancer
Sophocarpine is one of the significant alkaloid extracted from the traditional herb medicine Sophora flavescens which has many pharmacological properties such as anti-virus, anti-tumor, anti-inflammatory. Sophocarpine significantly inhibits the growth of gastric cancer (GC) cells through multiple mechanisms such as induction of autophagy, activation of cell apoptosis and down-regulation of cell survival PI3K/AKT signaling pathway. Sophocarpine has been demonstrated to have anti-tumor activity in various cancer cells, including hepatocellular carcinoma, prostate cancer and colorectal cancer .

HY-150753

RS6212	Oxidative Phosphorylation Lactate Dehydrogenase	Cancer
RS6212 is a specific LDH (lactate dehydrogenase) inhibitor with an IC₅₀ value of 12.03 μM . RS6212 inhibits tumor growth and exhibits potent anticancer activity in multiple cancer cell lines .

HY-136123

Tubulin inhibitor 8	Microtubule/Tubulin	Cancer
Tubulin inhibitor 8 (Compound 33b) is a tubulin inhibitor and a potent inhibitor of multiple cancer cell lines. Tubulin inhibitor 8 inhibits tubulin polymerization with an IC₅₀ of 0.73 μM. Tubulin inhibitor 8 inhibits K562 cell growth with an IC₅₀ of 14 nM .

HY-136122

Tubulin inhibitor 7	Microtubule/Tubulin	Cancer
Tubulin inhibitor 7 (Compound 33c) is a tubulin inhibitor and a potent inhibitor of multiple cancer cell lines. Tubulin inhibitor 7 inhibits tubulin polymerization with an IC₅₀ of 0.52 μM. Tubulin inhibitor 7 inhibits K562 cell growth with an IC₅₀ of 11 nM .

HY-167857

(Rac)-Glutipyran	GLUT	Cancer
(Rac)-Glutipyran is a broad-spectrum GLUT inhibitor that targets both GLUT1 and GLUT3. (Rac)-Glutipyran inhibits glucose uptake and suppresses the growth of multiple cancer cells, significantly inhibiting PANC-1 cell growth (IC₅₀=1.8 μM) and glucose uptake (IC₅₀=0.13 μM) .

HY-N0103A

Sophocarpine monohydrate 5 Publications Verification	Autophagy Apoptosis PI3K Akt Influenza Virus	Infection Inflammation/Immunology Cancer
Sophocarpine (monohydrate) is one of the significant alkaloid extracted from the traditional herb medicine Sophora flavescens which has many pharmacological properties such as anti-virus, anti-tumor, anti-inflammatory. Sophocarpine (monohydrate) significantly inhibits the growth of gastric cancer (GC) cells through multiple mechanisms such as induction of autophagy, activation of cell apoptosis and down-regulation of cell survival PI3K/AKT signaling pathway. Sophocarpine (monohydrate) has been demonstrated to have anti-tumor activity in various cancer cells, including hepatocellular carcinoma, prostate cancer and colorectal cancer .

HY-151595

Menin-MLL inhibitor-22	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor-22 (compound C20) is an orally active inhibitor of the interaction between menin and mixed lineage leukemia (MLL) (IC₅₀=7 nM). Menin-MLL inhibitor-22 binds menin protein and inhibits cancer cell growth (MV4 cells, IC₅₀=0.3 μM). Menin is a putative tumor suppressor associated with multiple endocrine neoplasia type 1 (MEN-1 syndrome) .

HY-N0103R

Sophocarpine (Standard)	Autophagy Apoptosis PI3K Akt Influenza Virus	Infection Inflammation/Immunology Cancer
Sophocarpine (Standard) is the analytical standard of Sophocarpine. This product is intended for research and analytical applications. Sophocarpine is one of the significant alkaloid extracted from the traditional herb medicine Sophora flavescens which has many pharmacological properties such as anti-virus, anti-tumor, anti-inflammatory. Sophocarpine significantly inhibits the growth of gastric cancer (GC) cells through multiple mechanisms such as induction of autophagy, activation of cell apoptosis and down-regulation of cell survival PI3K/AKT signaling pathway. Sophocarpine has been demonstrated to have anti-tumor activity in various cancer cells, including hepatocellular carcinoma, prostate cancer and colorectal cancer .

HY-124757

FiVe1	Proteasome	Inflammation/Immunology
FiVe1 is a potent vimentin (VIM; the intermediate filament and mesenchymal marker) inhibitor . FiVe1 promotes VIM disorganization and phosphorylation during metaphase, leading to mitotic catastrophe, multinucleation, and the loss of stemness.?FiVe1 selectively and irreversibly inhibits the growth of multiple FOXC2-expressing breast cancer cell lines (HMLER cells (IC₅₀:?267 nM); FOXC2-HMLER cells (IC₅₀:?447 nM). FiVe1 inhibits the migration of mesenchymally transformed cells .

HY-155028

FGFR-IN-11	FGFR	Cancer
FGFR-IN-11 (compound I-5) is an orally active and covalent FGFR inhibitor with IC₅₀ values of 9.9 nM (FGFR1), 3.1 nM (FGFR2), 16 nM (FGFR3), and 1.8 nM (FGFR4), respectively. FGFR-IN-11 inhibits multiple cancer cell proliferation with nanomolar activity. FGFR-IN-11 inhibits tumor growth significantly in xenograft mice models .

HY-P99361

Enavatuzumab PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)	TNF Receptor	Cancer
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .

HY-Y0790R

Cuminaldehyde (Standard)	Endogenous Metabolite Apoptosis DNA/RNA Synthesis α-synuclein Lipoxygenase Opioid Receptor Interleukin Related TNF Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
Cuminaldehyde (Standard) is the analytical standard of Cuminaldehyde. This product is intended for research and analytical applications. Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC₅₀= 0.00085 mg/mL) and α-glucosidase (IC₅₀=0.5 mg/mL). Cuminaldehyde can modulate α-synuclein fibrils. Cuminaldehyde can induce apoptosis in colon adenocarcinoma cells by targeting topoisomerase I and II. In addition, Cuminaldehyde also exerts anti-inflammatory activity by inhibiting lipoxygenase. Cuminaldehyde has a strong inhibitory effect on the growth of Aspergillus flavus and the biosynthesis of aflatoxin B1 (AFB1). Cuminaldehyde can exert anti-injury and anti-neuropathy effects by participating in opioid receptors, L-arginine/NO/cGMP pathways and anti-inflammatory effects. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .

Cat. No.	Product Name

HY-L083

Anti-Cancer Metabolism Compound Library	2,327 compounds
Mutations in oncogenes and tumor suppressor genes can modify multiple signaling pathways and in turn cell metabolism, which facilitates tumorigenesis. The paramount hallmark of tumor metabolism is “aerobic glycolysis” or the Warburg effect, coined by Otto Warburg in 1926, in which cancer cells produce most of energy from glycolysis pathway regardless of whether in aerobic or anaerobic condition. Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside. The increased uptake of glucose is facilitated by the overexpression of several isoforms of membrane glucose transporters (GLUTs). Likewise, the metabolic pathways of glutamine, amino acid and fat metabolism are also altered. Recent trends in anti-cancer drug discovery suggests that targeting the altered metabolic pathways of cancer cells result in energy crisis inside the cancer cells and can selectively inhibit cancer cell proliferation by delaying or suppressing tumor growth. MCE provides a unique collection of 2,327 compounds which cover various tumor metabolism-related signaling pathways. These compounds can be used for anti-cancer metabolism targets identification, validation as well anti-cancer drug discovery.

Anti-Cancer Metabolism Compound Library

2,327 compounds

Mutations in oncogenes and tumor suppressor genes can modify multiple signaling pathways and in turn cell metabolism, which facilitates tumorigenesis. The paramount hallmark of tumor metabolism is “aerobic glycolysis” or the Warburg effect, coined by Otto Warburg in 1926, in which cancer cells produce most of energy from glycolysis pathway regardless of whether in aerobic or anaerobic condition. Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside. The increased uptake of glucose is facilitated by the overexpression of several isoforms of membrane glucose transporters (GLUTs). Likewise, the metabolic pathways of glutamine, amino acid and fat metabolism are also altered. Recent trends in anti-cancer drug discovery suggests that targeting the altered metabolic pathways of cancer cells result in energy crisis inside the cancer cells and can selectively inhibit cancer cell proliferation by delaying or suppressing tumor growth.

MCE provides a unique collection of 2,327 compounds which cover various tumor metabolism-related signaling pathways. These compounds can be used for anti-cancer metabolism targets identification, validation as well anti-cancer drug discovery.

Cat. No.	Product Name	Target	Research Area